Featured Research

from universities, journals, and other organizations

Animal Research Suggests New Treatment Target For Epilepsy

Date:
July 4, 2005
Source:
Wake Forest University Baptist Medical Center
Summary:
New research suggests novel treatment targets for the most common form of childhood epilepsy -- with the potential to have fewer side effects than traditional therapy. The findings from Wake Forest University School of Medicine are reported in the July issue of the Journal of Neurophysiology.

WINSTON-SALEM, N.C. -- New research suggests novel treatment targets for the most common form of childhood epilepsy -- with the potential to have fewer side effects than traditional therapy. The findings from Wake Forest University School of Medicine are reported today in the July issue of the Journal of Neurophysiology.

Through studies in animals, the researchers learned more about the possible brain pathways involved in absence, or petit mal, seizures and tested a drug that revealed a potential new target for blocking seizures before they spread.

"Many current therapies act on the entire nervous system and can have such side effects as sleep disruptions, dizziness and increased risk of developmental side effects," said Georgia Alexander, who with Dwayne Godwin, Ph.D., co-authored the new study. "Because this treatment blocks the pathway that may cause the spread of seizures, it could be more effective and have fewer side effects."

Absence seizures, which are most common in children between 6 and 12, get their name because during the seizure the child seems to be temporarily unconscious of his or her surroundings. Although they last only a few seconds, the seizures can occur hundreds of times a day and can dramatically impact learning and development.

Doctors don't know exactly what causes the seizures, but a prevalent theory is that an abnormal electrical discharge originates in the cerebral cortex, the part of the brain that controls thinking and feeling, and travels to the thalamus, a part of the brain that controls consciousness and certain brain rhythms. The abnormal rhythmic discharges that result may then spread to other parts of the brain. Other types of seizures may also spread this way, including Lennox-Gastaut seizures, a severe form of childhood epilepsy that is often resistant to treatment.

"We know that the cortex communicates with the thalamus continuously, and current theories suggest that when the 'conversation' gets too loud, seizures can occur," said Alexander. "We wanted to see if there was a way to calm the dialog."

In studying this possible pathway of seizures, Alexander made an important finding about its organization. It was already known that cells in the thalamus communicate with cells in the cortex by releasing the neurotransmitter glutamate. The glutamate travels across the gap -- creating a pathway for cell-to-cell communication.

Alexander and Godwin were the first to show that in addition to releasing glutamate, thalamus cells also have a special type of glutamate receptor that acts almost as a braking system -- slowing the release of glutamate when there is high-intensity brain activity associated with a seizure.

"It's like the gas and brake pedals of your car, "said Godwin, associate professor of neurobiology and anatomy and the senior researcher on the project. "Glutamate is important for normal communication in the brain, but sometimes it's necessary to put on the brakes in order to preserve normal function. This receptor appears to slow down the rate at which glutamate is released across the synaptic gap, and may protect the cells from becoming overexcited."

Alexander hypothesizes that in epilepsy patients, the protective receptors may not function well or that glutamate production may be abnormal. A treatment that targets these protective glutamate receptors has the potential to block the pathway involved in seizures, with the added benefit of allowing normal communication to continue.

"If this research leads to drugs that can target these newly discovered receptors, it would be an important advance in therapy," said William L. Bell, M.D., a specialist in epilepsy at Wake Forest University Baptist Medical Center.

Godwin explained that design of improved drugs to target the receptors wouldn't be a cure, but would short-circuit the type of abnormal activity that results in seizures.

In this research, the scientists studied the pathway by simulating seizure-related activity within brain circuits. They will continue the research by studying animals that are genetically predisposed to epilepsy.

The research was funded by the National Institutes of Health.



Story Source:

The above story is based on materials provided by Wake Forest University Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University Baptist Medical Center. "Animal Research Suggests New Treatment Target For Epilepsy." ScienceDaily. ScienceDaily, 4 July 2005. <www.sciencedaily.com/releases/2005/07/050704110307.htm>.
Wake Forest University Baptist Medical Center. (2005, July 4). Animal Research Suggests New Treatment Target For Epilepsy. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/07/050704110307.htm
Wake Forest University Baptist Medical Center. "Animal Research Suggests New Treatment Target For Epilepsy." ScienceDaily. www.sciencedaily.com/releases/2005/07/050704110307.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins